Home › All Companies › BVS

Bioventus Inc. (BVS)

AI-Powered SEC Filing Analysis

Current Report Filed: 2026-05-06

Key Insights

  • Bioventus announced Q1 2026 financial results on May 6, 2026, indicating the company is maintaining regular earnings reporting cadence with results for the three months ended March 28, 2026.
  • The company is classified as an emerging growth company and has elected not to use the extended transition period for new accounting standards, suggesting management prioritizes compliance with full GAAP standards.
  • Filing was signed by Anthony D'Adamio, Senior Vice President and General Counsel, indicating routine quarterly earnings disclosure without extraordinary corporate events or material agreements mentioned.
Sentiment: Neutral Significance: 3/10
View Original Filing →
Quarterly Report Filed: 2026-05-06

Key Insights

  • The filing shows a Q1 2026 period (January 1 - March 28, 2026) with multiple debt facilities tracked, including term loans and revolving credit agreements under a Senior Secured Credit Agreement as of July 31, 2025, indicating active debt management and refinancing activities.
  • The presence of interest rate swap derivatives and multiple debt covenant ranges suggests Bioventus is actively managing interest rate risk exposure, reflecting a focus on protecting margins in a volatile rate environment.
  • Customer concentration risk is explicitly tracked in the filing with 'CustomerOneMember' identified in both Q1 2026 and full year 2025, signaling potential revenue dependency on a single major customer that warrants investor attention.
Sentiment: Neutral Significance: 4/10
View Original Filing →
Insider Trading Filed: 2026-04-14

Key Insights

  • Insider Anthony D'Adamio, the SVP & General Counsel, exercised 9,925 restricted stock units and disposed of 4,312 shares of Class A common stock, suggesting potential wealth diversification.
  • The transaction price of $9.06 per share suggests the stock is trading at a reasonable valuation compared to the exercise price of $0 for the restricted stock units.
  • The remaining 153,655 shares of Class A common stock held by Anthony D'Adamio indicate his continued alignment with Bioventus Inc.'s long-term success.
Sentiment: Neutral Significance: 5/10
View Original Filing →
Insider Trading Filed: 2026-04-14

Key Insights

  • Katrina J. Church, SVP & Chief Compliance Officer, exercised 4,300 restricted stock units and sold 1,868 shares of Class A common stock, reducing her direct ownership to 64,164 shares.
  • The transaction was executed on April 10, 2026, with the shares being sold at a price of $9.06 per share.
  • This insider transaction suggests that the executive is monetizing a portion of her equity holdings, which could indicate her confidence in the company's near-term performance or a personal financial need.
Sentiment: Neutral Significance: 4/10
View Original Filing →
Insider Trading Filed: 2026-04-14

Key Insights

  • Mark Leonard Singleton, the SVP & CFO of Bioventus Inc. (BVS), has exercised 13,000 restricted stock units (RSUs) and disposed of 5,648 shares of Class A common stock through a 'net settlement' transaction.
  • The exercised RSUs and the subsequent share disposition indicate that the reporting person is monetizing a portion of his equity-based compensation, which could signal his confidence in the company's financial performance.
  • The reported transaction represents a relatively small portion of the reporting person's total beneficial ownership, which remains at 177,333 shares of Class A common stock following the reported transactions.
Sentiment: Neutral Significance: 4/10
View Original Filing →
Insider Trading Filed: 2026-03-24

Key Insights

  • The reporting person, Mark Leonard Singleton, is the SVP & CFO of Bioventus Inc., indicating this is an important insider transaction.
  • Singleton exercised 18,625 restricted stock units (RSUs) and sold 8,091 shares, potentially to cover taxes, suggesting he continues to hold a significant equity stake in the company.
  • The timing and size of this transaction suggest the reporting person remains confident in Bioventus' long-term prospects, as he is not significantly reducing his ownership position.
Sentiment: Positive Significance: 6/10
View Original Filing →
Insider Trading Filed: 2026-03-17

Key Insights

  • The reporting person, Robert E. Claypoole, acquired 134,000 restricted stock units and 153,000 stock options, indicating potential confidence in the company's future performance.
  • Claypoole also disposed of 14,553 shares of Class A common stock, likely for tax or liquidity purposes, but maintains a sizable ownership stake of 135,944 shares.
  • The vesting schedule of the restricted stock units and stock options suggests a long-term incentive alignment between Claypoole and Bioventus Inc. shareholders.
Sentiment: Positive Significance: 6/10
View Original Filing →
Insider Trading Filed: 2026-03-17

Key Insights

  • The reporting person, Anthony D'Adamio, who is the SVP and General Counsel of Bioventus Inc. (BVS), made multiple transactions involving the company's Class A common stock and derivative securities.
  • D'Adamio exercised 8,886 restricted stock units (RSUs) and 8,750 RSUs, and then sold 3,861 and 3,802 shares to cover tax withholding, indicating continued ownership and vesting of equity awards.
  • The reporting person also received new grants of 35,000 RSUs and 40,000 stock options, as well as an additional 83,000 RSUs and 92,000 stock options, vesting over the next four years, signaling long-term incentive alignment with shareholders.
Sentiment: Positive Significance: 6/10
View Original Filing →
Insider Trading Filed: 2026-03-17

Key Insights

  • Insider Katrina J. Church, SVP & Chief Compliance Officer, exercised 6,955 stock options and restricted stock units, indicating ongoing commitment to the company.
  • Church sold 3,022 shares to cover tax withholding obligations, suggesting she is not cashing out a significant portion of her holdings.
  • The reported transactions align with Church's previous equity awards, suggesting a routine exercise of vested equity rather than a material change in her ownership position.
Sentiment: Positive Significance: 4/10
View Original Filing →
Insider Trading Filed: 2026-03-17

Key Insights

  • Insider Mark Leonard Singleton, SVP & CFO of Bioventus Inc. (BVS), exercised 13,500 stock options and sold 5,865 shares, indicating he is reducing his direct ownership in the company.
  • Singleton received 54,000 new restricted stock units (RSUs) and 61,000 stock options, which will vest in four equal installments over the next four years, aligning his interests with the company's long-term performance.
  • The company appears to be providing Singleton with a significant equity-based compensation package, which could be a sign of the board's confidence in his leadership and the company's future prospects.
Sentiment: Neutral Significance: 6/10
View Original Filing →
Current Report Filed: 2026-03-05

Key Insights

  • Bioventus reported its Q4 2025 and full-year 2025 financial results, indicating the company's continued growth and strong performance.
  • The press release highlights Bioventus' revenue growth and improvement in key financial metrics, suggesting the company is executing well on its business strategy.
  • Investors may be interested in the company's guidance and any notable trends or developments discussed in the earnings report.
Sentiment: Positive Significance: 6/10
View Original Filing →
Annual Report Filed: 2026-03-05

Key Insights

  • Bioventus Inc. (BVS) reported a decline in revenue and profitability in 2025 compared to previous years, which could raise concerns for investors.
  • The company has significant exposure to supplier concentration risk, with four key suppliers accounting for a substantial portion of its revenue and accounts payable.
  • Bioventus has made investments in property, plant, and equipment, as well as intangible assets like intellectual property and developed technology rights, which could impact its cash flow and financial position.
Sentiment: Negative Significance: 6/10
View Original Filing →
Insider Trading Filed: 2026-01-13

Key Insights

  • Insider Robert E. Claypoole, who is the President and CEO, acquired 93,750 shares of Bioventus Inc. (BVS) through the vesting of restricted stock units (RSUs) on January 9, 2026.
  • Claypoole then sold 41,717 shares to cover tax withholding obligations, leaving him with a net increase of 52,033 shares in his direct ownership.
  • The reported transactions suggest that Claypoole remains confident in the company's outlook and is aligning his interests with shareholders by maintaining a substantial direct ownership stake.
Sentiment: Positive Significance: 6/10
View Original Filing →

Get real-time filing analysis in the app

Download on the App Store

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.